Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group
Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group
Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
50
Years old
Gender
Female
Therapeutic area :
Vascular
Disease :
Venous lymphatic insufficiency symptom
Study medication :
Dc982ge (Cyclo 3 Fort®)
Phase :
Phase II
Start Date :
07 December 2009
End date :
09 November 2010
Study ID :
DC0982 GE 203 1B
EudraCT/CTIS number :
2009-014681-25
Send by email